Disulfide bonds as switches for protein function

Trends in Biochemical Sciences

Volumn 28, Issue 4, 2003, Pages 210-214

  Hogg, Philip J ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; DISULFIDE; DITHIOL DERIVATIVE; PROTEIN;

ACIDITY; ALKALINITY; CATALYST; DISULFIDE BOND; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STABILITY; REVIEW;

EID: 0037397499     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(03)00057-4     Document Type: Review

References (60)

1. Thornton J.M. Disulphide bridges in globular proteins. J. Mol. Biol. 151:1981;261-287.
2. Wetzel R. Harnessing disulfide-bonds using protein engineering. Trends Biochem. Sci. 12:1987;478-482.
3. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 17:2001;25-51.
4. Lawler J., Hynes R.O. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J. Cell Biol. 103:1986;1635-1648.
5. Speziale M.V., Detwiler T.C. Free thiols of platelet thrombospondin. J. Biol. Chem. 265:1990;17859-17867.
6. Sun X., et al. Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin. J. Cell Biol. 118:1992;693-701.
7. Hogg P.J. Thrombospondin 1 as an enzyme inhibitor. Thromb. Haemost. 72:1994;787-792.
8. Misenheimer T.M., Mosher D.F. Calcium ion binding to thrombospondin 1. J. Biol. Chem. 270:1995;1729-1733.
9. Hogg P.J., et al. Interaction of platelet-derived growth factor with thrombospondin 1: dependence on the disulfide-bond arrangement in thrombospondin 1. Biochem. J. 326:1997;709-716.
10. Matthias L.J., et al. Identification of monoclonal antibodies that recognize different disulfide-bonded forms of thrombospondin 1. Biochim. Biophys. Acta. 1296:1996;138-144.
11. Hotchkiss K.A., et al. Catalysis of disulfide isomerization in thrombospondin 1 by protein disulfide isomerase. Biochemistry. 35:1996;9761-9767.
12. Milev Y., Essex D.W. Protein disulfide isomerase catalyzes the formation of disulfide-linked complexes of thrombospondin-1 with thrombin-antithrombin III. Arch. Biochem. Biophys. 361:1999;120-126.
13. Chen K., et al. Characterization of protein disulfide isomerase released from activated platelets. Br. J. Haematol. 90:1995;425-431.
14. Essex D.W., et al. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood. 86:1995;2168-2173.
15. Yoshimori T., et al. Protein disulfide-isomerase in rat exocrine pancreatic cells is exported from the endoplasmic reticulum despite possessing the retention signal. J. Biol. Chem. 265:1990;15984-15990.
16. Terada K., et al. Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. J. Biol. Chem. 270:1995;20410-20416.
17. Lawrence D.A., et al. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. J. Leukoc. Biol. 60:1996;611-618.
18. Tager M., et al. Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp. Hematol. 25:1997;601-607.
19. Jiang X.-M., et al. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J. Biol. Chem. 274:1999;2416-2423.
20. Xie L., et al. Control of von Willebrand factor multimer size by thrombospondin-1. J. Exp. Med. 193:2001;1341-1349.
21. Pimanda J.E., et al. The von Willebrand Factor reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood. 100:2002;2832-2838.
22. Stathakis P., et al. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J. Biol. Chem. 272:1997;20641-20645.
23. Stathakis P., et al. Angiostatin formation involves disulfide-bond reduction and proteolysis in kringle 5 of plasmin. J. Biol. Chem. 274:1999;8910-8916.
24. O'Reilly M.S., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
25. Lay A.J., et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature. 408:2000;869-873.
26. Lay A.J., et al. Plasmin reduction by phosphoglycerate kinase is a thiol-independent process. J. Biol. Chem. 277:2002;9062-9068.
27. Kwon M., et al. Identification of annexin II heterotetramer as a plasmin reductase. J. Biol. Chem. 277:2002;10903-10911.
28. Gately S., et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. U. S. A. 94:1997;10868-10872.
29. Kassam G., et al. Purification and characterization of A61. An angiostatin-like plasminogen fragment produced by plasmin autodigestion in the absence of sulfhydryl donors. J. Biol. Chem. 276:2001;8924-8933.
30. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:2001;777-810.
31. Wang J.H., et al. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature. 348:1990;411-418.
32. Ryu S.E., et al. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature. 348:1990;419-426.
33. 2-terminal domains. Science. 260:1993;979-983.
34. Matthias L.J., et al. Disulfide exchange in domain 2 of CD4 is required for entry of the human immunodeficiency virus type 1. Nat. Immun. 3:2002;727-732.
35. Martin H., Dean M. Identification of a thioredoxin-related protein associated with plasma membranes. Biochem. Biophys. Res. Commun. 175:1991;123-128.
36. Rubartelli A., et al. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J. Biol. Chem. 267:1992;24161-24164.
37. Matthias L.J., Hogg P.J. Redox control on the cell surface: implications for HIV-1 entry. Antioxid. Redox Signal. 5:2003;133-138.
38. Gallina A., et al. Inhibitors of protein disulfide isomerase (PDI) prevent cleavage of disulfide-bonds in receptor-bound gp120 and prevent HIV-1 entry. J. Biol. Chem. 277:2002;50579-50588.
39. Barbouche R., et al. Protein disulfide isomerase-mediated reduction of two disulfide-bonds of HIV Env gp120 occurs post CXCR4 binding and is required for fusion. J. Biol. Chem. 278:2003;3131-3136.
40. Ryser H.J., et al. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4559-4563.
41. Fenouillet E., et al. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. J. Infect. Dis. 183:2001;744-752.
42. Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell. 110:2002;673-687.
43. Yan B., Smith J.W. Mechanism of integrin activation by disulfide-bond reduction. Biochemistry. 40:2001;8861-8867.
44. Yan B., Smith J.W. A redox site involved in integrin activation. J. Biol. Chem. 275:2000;39964-39972.
45. 3 has an endogenous thiol isomerase activity. J. Biol. Chem. 275:2000;36984-36990.
46. Lahav J., et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood. 100:2002;2472-2478.
47. Essex D.W., et al. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry. 40:2001;6070-6075.
48. 3. Science. 294:2001;339-345.
49. Beglova N., et al. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat. Struct. Biol. 9:2002;282-287.
50. Freedman R.B., et al. Protein disulfide isomerases exploit synergy between catalytic and specific binding domains. EMBO Rep. 3:2002;136-140.
51. Gagnon E., et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell. 110:2002;119-131.
52. Berridge M.V., Tan A.S. High-capacity redox control at the plasma membrane of mammalian cells: trans-membrane, cell surface, and serum NADH-oxidases. Antioxid. Redox Signal. 2:2000;231-242.
53. Brandt W., et al. A molecular mechanism for the cleavage of a disulfide-bond as the primary function of agonist binding to G-protein-coupled receptors based on theoretical calculations supported by experiments. Eur. J. Biochem. 261:1999;89-97.
54. Chang Y., et al. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry. 37:1998;3258-3271.
55. Richardson J.A. Protein anatomy. Adv. Protein Chem. 34:1981;167-339.
56. Weiner S.J., et al. A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Am. Chem. Soc. 106:1984;765-784.
57. Katz B.A., Kossiakoff A. The crystallographically determined structures of atypical strained disulfides engineered into subtilisin. J. Biol. Chem. 261:1986;15480-15485.
58. Wells J.A., Power D.B. In vivo formation and stability of engineered disulfide-bonds in subtilisin. J. Biol. Chem. 261:1986;6564-6570.
59. Lipton S.A., et al. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends Neurosci. 25:2002;474-480.
60. Ryu S.E., et al. Structures of an HIV and MHC binding fragment from human CD4 as refined in two crystal lattices. Structure. 2:1994;59-74.